Cancer News and Research

Latest Cancer News and Research

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company is set to be added to the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions updated on June 18 on www.russell.com.

21 Jun 2010

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study's design, timing and regulatory review.

21 Jun 2010

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

Recently, oral cancer survivor Jeanna Richelson, organized the first Chattanooga Oral Cancer Awareness Walk, which raised donations for the Oral Cancer Foundation, and much needed awareness of a disease that too few Americans know about. According to the foundation's executive director Brian Hill, "I don't believe there has ever been an oral cancer walk that was this successful in its first year. This was an absolutely amazing effort by Jeanna and those who helped her make this possible."

21 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

Researchers develop new drugs that relieve cancer pain without side effects

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

21 Jun 2010

EIN News expands health news-monitoring coverage

With impending lawsuits from states, an uprising from the Tea Party sect and an outpouring of rhetoric from both major parties, the healthcare debate is far from over.

21 Jun 2010

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Hepatic artery thrombosis, which is the most common vascular complication after living donor liver transplantation, can result in graft loss and devastating consequences. Surgical techniques are suggested to an important factor in causing HAT. Despite improvements in surgical techniques, arterial reconstruction in LDLT has a high risk of thrombosis.

21 Jun 2010

Consumers can now access high quality health and medical information on Internet using Medgateway.com

With the vast amount of medical information on the Internet, consumers can spend long hours looking for health and medical information. Consumers can access reliable, high quality health and medical information on the Internet using Medgateway.com. Medgateway provides links to numerous health and medical web sites.

21 Jun 2010

CPTC offers training program for firefighters to help reduce health-related deaths and injuries

Firefighter deaths due to heart attacks may not be due to bad diets, but from exposure to hydrogen cyanide in fire smoke. Nationally, six firefighters have literally dropped dead from heart attacks after coming off of a shift of smoky fires and more than 100 were treated or hospitalized for smoke inhalation since January 1.

21 Jun 2010

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.

21 Jun 2010

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

21 Jun 2010

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

19 Jun 2010

Research findings support the need to establish standards for DFSA care

New toxicology findings reveal the presence of drugs and/or alcohol in 76 per cent of women and men who suspect they were victims of drug-facilitated sexual assault. Of those, 64 per cent did not report voluntarily consuming the drugs found, supporting their belief that they may have been slipped a drug. In addition, unexpected male DNA was found in a substantial number of cases, confirming sexual activity.

19 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

Hyundai Hope on Wheels, a partnership of Hyundai dealers across the U.S. and Hyundai Motor America, today announced a new nationwide initiative to raise funds to fight childhood cancer. Hyundai dealers have pledged to donate a total of $3 million dollars to Hope on Wheels based on vehicles sold during the month of September (National Childhood Cancer Awareness Month).

19 Jun 2010

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

ExonHit Therapeutics today informs its shareholders that it learned on June 16, 2010 from RedPath Integrated Pathology that Highmark (the Medicare reimbursement regional antenna for the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania) announced its intention to discontinue coverage of PathFinderTG - Pancreatic cancer, contingent to a complementary assessment of the utility of the product.

19 Jun 2010

New insights into cancer hallmarks in induced pluripotent cells

The therapeutic potential of embryonic stem cells has been an intense focus of study and discussion in biomedical research and has resulted in technologies to produce human induced pluripotent stem cells (hiPSCs). Derived by epigenetic reprogramming of human fibroblasts, these hiPSCs are thought to be almost identical to human embryonic stem cells (hESCs) and provide great promise for patient-tailored regenerative medicine therapies.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

UKCMRI unveils vision for biggest biomedical research, innovation centre in Europe

The UK Centre for Medical Research and Innovation (UKCMRI) has unveiled its vision for the institute, which will be the biggest centre for biomedical research and innovation in Europe.

19 Jun 2010

Study measures relationship between individual exposure to arsenic and mortality risk

More than 20 percent of deaths in a study of 12,000 Bangladeshis were attributable to arsenic exposure from contaminated drinking water, new research reports.

19 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Inovio Pharmaceuticals set to be added to Russell 3000 Index

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

Cancer survivor organizes first Chattanooga Oral Cancer Awareness Walk

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

Researchers develop new drugs that relieve cancer pain without side effects

EIN News expands health news-monitoring coverage

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Consumers can now access high quality health and medical information on Internet using Medgateway.com

CPTC offers training program for firefighters to help reduce health-related deaths and injuries

Exelixis announces regaining of rights to develop and commercialize XL184

Prototype drug blocks MCL-1 protein that helps tumors survive treatment: Scientists

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

Research findings support the need to establish standards for DFSA care

Active surveillance sufficient for patients with low-risk prostate cancer

Hyundai Hope on Wheels announces nationwide initiative to raise funds for childhood cancer research

ExonHit Therapeutics informs shareholders about Highmark's intention to discontinue coverage of PathFinderTG

New insights into cancer hallmarks in induced pluripotent cells

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

UKCMRI unveils vision for biggest biomedical research, innovation centre in Europe

Study measures relationship between individual exposure to arsenic and mortality risk

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in